Argenx Q3 Net Income Rises to $506 Million on Strong VYVGART Sales; Shares Fall Pre-Market

Argenx SE (ARGX) reported higher third-quarter net income on Thursday, driven by continued growth of its VYVGART franchise. The company posted net income of $506 million, or $7.80 per diluted share, for the quarter ended September 30, 2026, up from $344 million, or $5.18 per diluted share, a year earlier. VYVGART product net sales rose to $1.721 billion from $1.127 billion. Total operating income increased to $1.751 billion from $1.151 billion. R&D expenses climbed to $503 million from $359 million, while SG&A expenses rose to $598 million from $336 million, including about $150 million tied to the Forte Biosciences acquisition. Cash and current financial assets totaled $3.7 billion as of September 30, 2026. The company submitted a U.S. application for VYVGART in ocular myasthenia gravis and received FDA priority review for pediatric generalized myasthenia gravis applications, with a decision targeted for February 2027. For the full year, Argenx expects combined R&D and SG&A expenses of approximately $4 billion. ARGX closed at $890.05, up 2.34%, but fell 3.43% to $859.50 in pre-market trading.